Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

View Full Paper
Ask AI
Bookmark
Share

Authors

RDRémy DuléryENEmma NicholsonHGHervé Ghesquières

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals CAR T-cell therapy shows lower progression-free survival and higher relapse incidence in large B-cell lymphoma compared to auto-HSCT.

Key Points

  • CAR T-cell therapy resulted in an inferior 2-year progression-free survival of 58.3% compared to 66.3% for auto-HSCT.
  • After a median follow-up of 2.0 years, 2-year overall survival was reported at 70.6% for CAR T-cell therapy versus 80.0% for auto-HSCT.
  • Multivariate Cox model showed no significant differences in outcomes like progression-free survival or overall survival between both therapies.
  • Auto-HSCT remains a valid therapeutic option for fit, transplant-eligible patients with large B-cell lymphoma in complete remission.

Cite This Study

Duléry et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db80https://doi.org/10.1182/blood-2025-2744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  2. 2Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory B-cell lymphomas: A systematic review and meta-analysis2025
  3. 3Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy2025 · 1 citations
  4. 4Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  5. 5Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy2025